RAINIER is a global About RAINIER
The efficacy and safety of povetacicept 80 mg versus placebo, in addition to standard of care, in approximately 480 patients with IgAN. The study will monaco email list 100000 contact leads conduct a preplann interim analysis design to evaluate the urine proteintocreatinine ratio (UPCR) of the povetacicept group versus the placebo group after a certain number of patients complete 36 weeks of treatment. If the results are positive, the interim analysis could serve as the basis for Vertex’s accelerat approval in the Unit States. The final analysis will be perform after two years of treatment, with the primary endpoint being the total eGFR slope at week 104.
The Phase 3 clinical study is being conduct in multiple regions including
The Unit States, the European Union and Asia. Among them, Chinese regulators have approv RAINIER’s clinical trial application (CTA), and the study is currently underway.
About RUBY3
RUBY3 is an ongoing, multiplose escalation, multicohort, openlabel, Phase 1/2 basket study of povetacicept in autoimmune glomerulonephritis (including IgA nephropathy, primary membranous nephropathy, lupus nephritis, and ANCAassociat vasculitis with glomerulonephritis), in which povetacicept will be administer subcutaneously for up to 104 weeks.
About Zai Lab
Zai Lab (NASDAQ: ZLAB; HKEX: 9688) is an innovative, researchbas, commercialstage
biopharmaceutical company headquarter in generation z as a target audience China and the
Unit States. We are committ to addressing large unmet mical nes in oncology, immunology,
neuroscience and infectious diseases through the discovery, development and commercialization
of innovative products. Our goal is to use our capabilities and resources to strive to promote the health and wellbeing of people in China and around the world. For more information about Zai Lab, please visit www.zailaboratory.com or follow the company’s official WeChat account: Zai Lab.
Zai Lab ForwardLooking Statements
This press release contains forwardlooking trust review statements concerning
Zai Lab’s future expectations, plans and prospects, including, but not limit to,
statements regarding our prospects and plans for the development and commercialization
of POWER in Greater China and Singapore, the potential benefits of POWER, and potential treatments for IgA nephropathy and other Bcellmiat diseases RAINIER is a global.
